Published in Science on April 02, 2015
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma | NCT00683670
TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor | NCT03185429
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med (2016) 2.36
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med (2016) 1.52
The Basis of Oncoimmunology. Cell (2016) 1.47
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34
Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest (2015) 1.24
Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13
Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. Mol Cell Proteomics (2015) 1.05
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov (2016) 0.96
pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med (2016) 0.94
Cancer immunotherapy targeting neoantigens. Semin Immunol (2015) 0.92
Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses. Front Immunol (2015) 0.92
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med (2016) 0.92
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91
Cancer immunotherapy. Neo approaches to cancer vaccines. Science (2015) 0.86
Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother (2016) 0.86
Targeting neoantigens for cancer immunotherapy. Int Immunol (2016) 0.84
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun (2016) 0.82
The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. J Immunol (2016) 0.82
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines (2016) 0.82
Distinct Transcriptional Programs Control Cross-Priming in Classical and Monocyte-Derived Dendritic Cells. Cell Rep (2016) 0.82
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol (2015) 0.82
Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment. Nat Med (2016) 0.82
Dendritic cell-based immunotherapy. Cell Res (2016) 0.81
Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer (2017) 0.81
Mastering variation: variance components and personalised medicine. Stat Med (2015) 0.81
Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer (2016) 0.79
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78
Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Mol Oncol (2015) 0.78
INTEGRATE-Neo: A pipeline for Personalized Gene Fusion Neoantigen Discovery. Bioinformatics (2016) 0.78
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
Landscape of Tumor Antigens in T Cell Immunotherapy. J Immunol (2015) 0.77
Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol (2016) 0.77
A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol (2016) 0.77
Unmasking targets of antitumor immunity via high-throughput antigen profiling. Curr Opin Biotechnol (2016) 0.77
Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma. Cancer J (2017) 0.76
Current tools for predicting cancer-specific T cell immunity. Oncoimmunology (2016) 0.76
DNA sequencing technologies: 2006-2016. Nat Protoc (2017) 0.76
Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunol Res (2016) 0.76
Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. Hum Vaccin Immunother (2016) 0.76
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer (2016) 0.76
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials (2017) 0.76
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol (2017) 0.75
Prediction and prioritization of neoantigens: integration of RNA-Seq data with whole-exome sequencing. Cancer Sci (2016) 0.75
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology (2016) 0.75
TAP-ing into TIEPPs for cancer immunotherapy. J Clin Invest (2016) 0.75
A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. J Biomed Sci (2016) 0.75
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Med (2017) 0.75
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol (2017) 0.75
Dendritic Cell Therapies for Hematologic Malignancies. Mol Ther Methods Clin Dev (2017) 0.75
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med (2016) 0.75
Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol (2016) 0.75
Immunotherapy for Breast Cancer: What Are We Missing? Clin Cancer Res (2017) 0.75
AACR Cancer Progress Report 2015. Clin Cancer Res (2015) 0.75
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother (2016) 0.75
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology (2016) 0.75
Precision medicine driven by cancer systems biology. Cancer Metastasis Rev (2017) 0.75
Cancer Genomics. F1000Res (2015) 0.75
Clinical genetics. Sequencing for tailored melanoma immunotherapy. Nat Rev Genet (2015) 0.75
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. J Immunol Res (2015) 0.75
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Med (2016) 0.75
Putting T cells to work-outsourcing neoantigen detection in head and neck cancers? Oral Dis (2016) 0.75
IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma. Oncotarget (2016) 0.75
Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. Oncoimmunology (2016) 0.75
A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients. Oncotarget (2016) 0.75
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer (2017) 0.75
Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. Oncoimmunology (2016) 0.75
Researchers push for personalized tumour vaccines. Nature (2016) 0.75
Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccin Immunother (2016) 0.75
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med (2017) 0.75
Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity. J Immunol Res (2016) 0.75
Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. Oral Oncol (2016) 0.75
Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. Yale J Biol Med (2015) 0.75
Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases. Am J Transl Res (2015) 0.75
Immune evasion pathways and the design of dendritic cell-based cancer vaccines. Discov Med (2016) 0.75
Identification of the core regulators of the HLA I-peptide binding process. Sci Rep (2017) 0.75
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. Oncoimmunology (2016) 0.75
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology (2016) 0.75
TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines. Curr Opin Immunol (2017) 0.75
The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy. Front Immunol (2017) 0.75
Towards a better cancer precision medicine: systems biology meets immunotherapy. Curr Opin Syst Biol (2017) 0.75
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol (2017) 0.75
TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection. R Soc Open Sci (2017) 0.75
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab (2017) 0.75
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists. Cancer Immunol Immunother (2017) 0.75
Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines (2016) 0.75
Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. Cancer J (2017) 0.75
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology (2017) 0.75
Breast cancer neoantigens can induce CD8 T cell responses and antitumor immunity. Cancer Immunol Res (2017) 0.75
Neoantigen Vaccines Pass the Immunogenicity Test. Trends Mol Med (2017) 0.75
Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol (2017) 0.75
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells. Nat Commun (2017) 0.75
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Ensembl 2013. Nucleic Acids Res (2012) 11.70
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci (2003) 5.94
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res (2008) 4.53
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol (1993) 4.23
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 3.96
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun (2013) 2.72
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014) 2.50
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol (1989) 2.32
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014) 2.27
A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood (2014) 1.92
Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med (2013) 1.72
High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur J Immunol (2014) 1.71
Ultra-sensitive detection of rare T cell clones. J Immunol Methods (2011) 1.64
Cancer: evolution within a lifetime. Annu Rev Genet (2014) 1.44
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest (2013) 1.36
Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery. Biochemistry (2005) 1.26
Re-sequencing expands our understanding of the phenotypic impact of variants at GWAS loci. PLoS Genet (2014) 1.25
Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol (2010) 1.18
Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proc Natl Acad Sci U S A (2008) 1.18
A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J Immunol Methods (1993) 1.14
Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. J Immunol Methods (2010) 1.07
cDNA hybrid capture improves transcriptome analysis on low-input and archived samples. J Mol Diagn (2014) 1.03
Identification of class I HLA T cell control epitopes for West Nile virus. PLoS One (2013) 0.91
Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells. J Immunol (2012) 0.87